OpenAI 收购 Orchestra Bio
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development.
AI 导读
OpenAI 宣布收购 Orchestra Bio，该平台帮助生物制药团队协调复杂的药物研发流程。OpenAI 表示将基于其生命科学研究模型与工具 Rosalind 继续构建，以简化这些运营流程，让新疗法更快惠及患者。
正文
当前显示原文，中文全文译文尚未就绪。
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development.
Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner.
Welcome @ashokaraj_ and team!